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Summary
Actinobacteria produce numerous antibiotics and other specialised metabolites 
with important applications in medicine and agriculture1. Diffusible hormones 
frequently control the production of such metabolites by binding TetR family 
transcriptional repressors (TFTRs), but the molecular basis for this remains 
unclear2. The production of methylenomycin antibiotics in Streptomyces coelicolor
A3(2) is initiated by binding of 2-alkyl-4-hydroxymethylfuran-3-carboxylic acid 
(AHFCA) hormones to the TFTR MmfR3. Here, we report the X-ray crystal structure 
of an MmfR-AHFCA complex, establishing the structural basis for hormone 
recognition. We also elucidate the mechanism for DNA release upon hormone 
binding by single particle cryo-electron microscopy of an MmfR-operator complex. 
DNA binding and release assays with MmfR mutants and synthetic AHFCA 
analogues illuminate the role played by individual amino acid residues and 
hormone functional groups in ligand recognition and DNA release. These findings 
will facilitate the exploitation of Actinobacterial hormones and their associated 
TFTRs in synthetic biology and novel antibiotic discovery. 
3
Introduction 
Actinobacteria typically have a complex life cycle that proceeds from spore 
germination, through branched multi-nucleoid hyphae, to aerial hyphae, which 
septate into mono-nucleoid compartments that become spores4. Specialised 
metabolite production is coordinated with this cycle, usually commencing at the 
onset of aerial growth5. 
Diffusible hormones frequently induce the expression of specialised metabolite 
biosynthetic gene clusters (BGCs) in Actinobacteria6. The archetypal example is 
A-factor, a -butyrolactone (GBL) that triggers aerial mycelium formation and 
production of the antibiotic streptomycin in Streptomyces griseus (Figure 1a)7. 
Binding of A-factor to ArpA, a TetR family transcriptional repressor (TFTR), 
releases it from the promoter of a transcriptional activator that induces the 
expression of genes controlling morphogenesis and antibiotic biosynthesis (Figure 
1b)7. 
Antibiotic production (and in some cases morphogenesis) is controlled by 
analogous mechanisms in several other Actinobacteria. For many years, GBLs 
were believed to be only hormones involved. However, over the past decade three 
additional hormone classes have been implicated in the induction of antibiotic 
biosynthesis via binding to ArpA-like TFTRs (Figure 1a)3,8,9. Moreover, such TFTRs 
regulate the biosynthesis of several commercially important metabolites, but the 
hormones these respond to are mostly unknown2. 
Methylenomycin A is an antibiotic produced by Streptomyces coelicolor A3(2) 
(Figure 1c)10. We previously reported that a group of five AHFCAs called the 
methylenomycin furans (MMFs) induce the production of methylenomycin A in S. 
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coelicolor3. A three-gene operon (mmfLHP) at one end of the methylenomycin BGC 
directs MMF biosynthesis (Figure 1c)11. The divergent mmfR gene upstream of this 
operon encodes an ArpA-like TFTR that is hypothesized to bind the mmfR-mmfL, 
and mmyB-mmyY intergenic regions11. Binding of the MMFs to MmfR is proposed 
to release it from these regions, allowing mmyB, which encodes an activator of the 
methylenomycin biosynthetic genes, to be expressed11. 
The mechanisms of ligand recognition and DNA release by TFTRs that regulate 
antibiotic resistance gene expression in Actinobacteria are well characterised 
(Extended Data Figure 1a)12-14. However, the architecture of ArpA-like TFTRs and 
their DNA complexes differs significantly from these15,16, and the molecular basis 
for hormone recognition and DNA release are poorly understood.  Here we report 
structures of MmfR bound to an AHFCA and the operator from the mmfL-mmfR 
intergenic region, shedding light on hormone recognition and the mechanism of 
DNA release. We also report DNA binding and release assays employing wild type 
and mutant MmfR proteins, as well as a synthetic library of naturally occurring 
AHFCAs and analogues, which illuminate the role played by key amino acid 
residues and hormone functional groups in ligand recognition and DNA release. 
Results and Discussion 
MmfR DNA binding and release by MMFs 
Electrophoretic Mobility Shift Assays (EMSAs) with purified recombinant MmfR 
(Extended Data Figure 2a) showed that it binds the mmfL-mmfR and mmyB-mmyY
intergenic regions (Extended Data Figures 3a, 3b). Bioinformatics analyses 
identified homologous 18 bp pseudo-palindromic operator sequences, 
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hypothesised to be methylenomycin furan-autoregulator responsive elements 
(MAREs) in each of these intergenic regions11. Fluorescence anisotropy (FA) 
measurements with DNA duplexes containing MARE1 and MARE2 established 
that MmfR binds to both sequences (Extended Data Figure 4a). Subtle differences, 
in particular a terminal 5’-AAA…TTT-3’ sequence in MARE2 versus a 5’-
ATA…TAT-3’ sequence in MARE1, may explain the difference in affinity.  
The ability of each MMF produced by S. coelicolor to promote MmfR release from 
the mmfL-mmfR and mmyB-mmyY intergenic regions was confirmed using EMSAs 
(Extended Data Figures 3a, 3b and 4b). FA measurements determined the 
concentration of each hormone required for half maximal release (EC50) of MmfR 
from MARE1 and MARE2 (Extended Data Figure 4b; Supplementary Figures 2 and 
3). We also investigated the minimum quantity of each MMF needed to trigger 
methylenomycin production in S. coelicolor (Extended Data Figure 2b and 
Extended Data Table 1)3. 
In addition to AHFCAs, S. coelicolor produces GBLs that control expression of the 
coelimycin BGC by binding to the MmfR homologue ScbR17. To investigate 
whether MmfR is specific for AHFCAs or is also able to respond to other classes of 
hormone, we synthesised SCB1 (Extended Data Figure 5a), an abundant GBL in 
S. coelicolor. EMSAs showed that SCB1 cannot dissociate MmfR from the mmfL-
mmfR intergenic region (Extended Data Figure 3c), indicating no crosstalk between 
the AHFCA and GBL-dependent regulation systems in S. coelicolor. 
Crystal structure of MmfR-MMF2 complex
The X-ray crystal structures of MmfR and an MmfR-MMF2 complex were solved at 
1.5 Å resolution (Figure 2a; Extended Data Figure 6a). MmfR has a similar overall 
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fold to the putative GBL-dependent TFTR CprB (Extended Data Figure 6b, c). The 
first three α-helices form the DNA-binding domain (DBD) (Figure 2a)15 and α-
helices 4-9 constitute the hormone-binding domain (HBD), with α-helices 8 and 9 
form the homodimerisation interface (Figure 2a). The apo-protein and the MmfR-
MMF2 complex adopt very similar conformations (Figure 2b). 
Ten residues in the hormone-binding site interact directly with MMF2 (Figure 2c). 
Six form a hydrophobic pocket (L110, A113, W147, L151, V178, and F181) that 
accommodates the alkyl chain. The carboxylate group of the hormone accepts 
hydrogen bonds from the Y85 hydroxyl group, the backbone N-H group of Y144 
and an ordered water molecule, which also interacts with the backbone N-H group 
of W147. A second ordered water molecule is hydrogen bonded to the 
hydroxymethyl group of the hormone and the hydroxyl group of Y144. 
Cryo-EM structure of MmfR-DNA complex 
Attempts to crystallize MmfR bound to its operator were unsuccessful. We thus 
employed cryo-electron microscopy (cryo-EM) to elucidate the structure of the 
MmfR-DNA complex. The protein was complexed with a DNA duplex containing 
MARE1. Single particles of the complex were observed in cryo-EM movies (Figure 
2d). Two-dimensional classification of the particles showed they adopt several 
different orientations (Figure 2d). Three-dimensional classification and subsequent 
refinement yielded a 4.2 Å density map containing clearly defined secondary 
structure elements (Figure 2d and Extended Data Figure 7a-d). Superimposition of 
the MmfR X-ray structure onto the map indicated that the conformation of the DBD 
changes upon DNA binding (Extended Data Figure 7). Thus, we performed 
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molecular dynamics flexible fitting simulations to generate a model of the complex 
(Figure 2e).  
Two MmfR homodimers bind to opposite faces of the DNA duplex (Figure 2e, f). 
Hill coefficients >1 in the FA measurements indicate positive cooperativity in 
binding of the homodimers to MARE1 and MARE2 (Extended Data Figure 4a). The 
obtuse angle between the planes that bisect the monomers in each homodimer is 
140° (Figure 2f), consistent with other TFTRs that bind as homodimeric pairs 
(Extended Data Figure 6d-f)16,18,19. As in most other TFTR-DNA complexes, α-
helices 2 and 3 of MmfR, encompassing the helix-turn-helix motif, serve as spacer 
and recognition helices, respectively20. The intra-dimer distance between DBDs 
showed decreases from 47.6 Å in the protein-hormone complex to 37.6 Å in the 
protein-DNA complex (Figure 2a, e). The Cα atoms of the MmfR HBD in the 
hormone and DNA-bound states were superimposed to understand conformational 
changes that cause release of the protein from its operator upon hormone binding 
(Figure 2g). This revealed an upward shift of the DBD towards the HBD in the 
protein-hormone complex (Figure 2g), which prevents the helix-turn-helix from 
binding in the major groove of the DNA duplex. 
Comparison with other ArpA-like TFTRs
To develop insight into the molecular basis for hormone recognition and signal 
transduction from the HBD to the DBD, we aligned the sequence of MmfR with 
other ArpA-like TFTRs of known ligand specificity (Extended Data Figure 8a). The 
level of residue conservation was mapped onto the structure of the MmfR-MMF2 
complex (Extended Data Figure 8b and Figure 3).  
8
The W147, V178 and F181 residues, which form the sides of the alkyl chain binding 
pocket in MmfR, are very highly conserved in all other members of the ArpA family 
(Extended Data Figure 8a). While the three residues at the base of this pocket 
(L110, A113, L151) are highly conserved in AHFCA-binding TFTRs, they are less 
well conserved in proteins that bind other hormone classes (Extended Data Figure 
8a). This suggests that the alkyl chains common to the four known classes of ligand 
for ArpA-like TFTRs (Figure 1a) likely all bind in this hydrophobic pocket, with 
differences in residues at the base of the pocket reflecting differences in the length 
and/or polarity of the alkyl chain.     
The side chain NH2 group of Q130 in MmfR donates a hydrogen bond to the 
hydroxyl group of Y85, which is in direct contact with the carboxyl group of the 
AHFCA (Figure 3). Q130 and Y85 are conserved in AHFCA-binding TFTRs, but 
not other members of the ArpA family (Extended Data Figure 8a), whereas R128 
and L129, positioned opposite Q130 on -helix 6, are universally conserved in all 
ArpA-like TFTRs. The guanidinium group of R128 hydrogen bonds to the backbone 
carbonyl group of S44 and the side chain of L129 forms a hydrophobic contact with 
aromatic ring of the universally conserved F42 residue, which like S44 is located 
on -helix 1 (Figure 3). Similarly, the carboxylate group of E132, which is also on 
the opposite face of -helix 6 to Q130 and is very highly conserved in ArpA family 
members, hydrogen bonds to the backbone N-H and guanidinium groups of Y47 
and R128, respectively. The side chains of two other very highly conserved 
residues, I41, located on the opposite face of -helix 1 to F42, and V55, located on 
the top face of -helix 2, also form a hydrophobic contact. Polar contacts between 
R45 in -helix 1 and D54 in -helix 2, and D120 at the N-terminus of -helix 6 and 
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E36 in -helix 1 (via an ordered water molecule) are also quite highly conserved in 
ArpA homologues. This network of interactions suggests a plausible mechanism 
for signal transduction from the HBD to the DBD in MmfR. Binding of the 
carboxylate group of the hormone to the side chain of Y85 forces the C-terminal 
end of -helix 6 downward and the N-terminal end of -helix 4 inward (Figure 2g). 
This pulls the N-terminal end of -helix 1 towards the HBD, repositioning the helix-
turn-helix (Figure 2g and Extended Data Figure 1b). It seems likely that other ArpA 
family members employ a similar signal transduction mechanism. However, Y85 
and Q130 are not conserved, reflecting the structural differences between AHFCAs 
and the other hormone types.  
We created Y85F and Q130E mutants of MmfR to probe the role played by these 
residues in hormone binding and signal transduction. Binding of the mutant 
proteins to MARE1 and dissociation of the resulting complexes by MMF1 was 
determined using EMSAs and FA measurements (Extended Data Figure 3d and 
Supplementary Figure 4). In both cases, the mutant proteins bound tightly to the 
operator with positive cooperativity, but much higher concentrations of MMF1 were 
needed to dissociate them from MARE1. These results confirm that Y85 and Q130 
play an important role in recognition of the hormone and transmission of the signal 
from the HBD to the DBD in AHFCA-binding TFTRs.  
AHFCA structure-activity relationship 
Differences in the ability of MMFs1-5 to dissociate MmfR from its operators indicate 
that the alkyl chain is one determinant of hormone recognition by AHFCA-binding 
TFTRs. To further probe structural features that are important for hormone 
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recognition, a library of AHFCAs was synthesised (Extended Data Table 2 and 
Extended Data Figure 5b, c; Supplementary Figures 5-34). The dissociation of 
MmfR from MARE1 by these analogues was assessed using EMSAs (Extended 
Data Table 2 and Extended Data Figure 3e) and FA measurements enabled EC50
values to be determined in some cases (Extended Data Table 2 and 
Supplementary Figure 35).  
While moderate changes to the alkyl chain can be tolerated, more extensive 
changes strongly affect activity. Removal of the hydroxyl group from the 
hydroxymethyl substituent is tolerated, but other changes are not. It is surprising 
that the analogue with an altered hydroxymethyl substituent retains activity, 
because Y144 hydrogen bonds to the hydroxyl group via an ordered water 
molecule (Figure 2c). To verify that interaction of Y144 with the hydroxyl group is 
not critical for hormone recognition, we created a Y144F mutant of MmfR. FA 
measurements indicated that the affinity of this for MARE1 and the EC50 of MMF1 
were similar to the wild type protein (Supplementary Figure 4c). Induction of 
antibiotic production by the library in vivo showed analogous trends to DNA release 
in vitro (Extended Data Table 1). 
Conclusions 
Even though A-factor and ArpA were discovered fifty and twenty-five years ago, 
respectively2,7, the molecular mechanisms by which they control gene expression 
has remained unclear. The biosynthesis of several important medicines is 
controlled by TFTRs in the ArpA subfamily. A detailed understanding of the 
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molecular interactions between TFTRs, their operators and the hormones that 
control them could be exploited to improve the production of such molecules. 
Here, we have illuminated how binding of AHFCAs to ArpA-like TFTRs triggers 
antibiotic production in S. coelicolor. The crystal structure of MmfR complexed with 
MMF2 revealed the molecular basis for hormone recognition by AHFCA-binding 
TFTRs. In combination with the cryo-EM structure of MmfR bound to MARE1, this 
crystal structure identifies a conserved signal transduction mechanism in ArpA-like 
TFTRs (Extended Data Figure 1b). The DNA and ligand binding modes, and the 
signal transduction mechanism differ markedly from TFTRs that regulate antibiotic 
resistance gene expression (Extended Data Figure 1a). 
Only a handful of tetrameric TFTR-DNA structures have been determined in the 
last two decades, highlighting that X-ray crystallographic analysis remains 
challenging in these systems19. Our demonstration that such complexes can be 
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Figure Legends
Fig. 1 | Classes of Actinobacterial hormone that induce antibiotic production 
by binding TFTRs and proposed mechanism for regulation of 
methylenomycin A biosynthesis by AHFCAs. a, Representative structures of 
the four hormone classes – -butryolactones (GBLs), 2-alkyl-4-hydroxymethyl-
furan-3-carboxylic acids (AHFCAs), 4-alkylbutenolides (ABs) and 2-alkyl-4-
hydroxy-3-methylbutenolides (AHMBs) – known to control antibiotic production in 
Actinobacteria. b, Generalised mechanism for induction of antibiotic biosynthesis, 
involving hormone-mediated de-repression of a transcriptional activator by a TFTR. 
c, Proposed mechanism for regulation of methylenomycin A biosynthesis in S. 
coelicolor. MmfR is a TFTR that represses the mmfLHP operon, in addition to 
mmfR, mmyB and mmyY. The AHFCA concentration steadily increases due to low-
level expression of mmfLHP. Binding of the AHFCAs to MmfR upregulates 
mmfLHP expression, resulting in a feed forward loop. It also releases repression of 
the mmyB transcriptional activator of the methylenomycin biosynthetic genes.
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Fig. 2 | Structures of apo-MmfR, and the MmfR-MMF2 and MmfR-MARE1 
complexes determined by X-ray crystallography and cryo-EM. a, X-ray crystal 
structure of the homodimeric MmfR-MMF2 complex; HBD = hormone-binding 
domain; DBD = DNA-binding domain. b, Overlay of the C atoms of apo-MmfR and 
the MmfR-MMF2 complex (RMSD 0.447 Å for the 159 C atoms). c, Key residues 
lining the MmfR hormone-binding pocket, highlighting polar interactions (dashed 
lines) between MmfR (yellow) and MMF2 (cyan), in two cases mediated by ordered 
water molecules (purple spheres). All distances are in Å. d, Representative cryo-
EM micrograph of MmfR-MARE1 complex (top, scale bar: 30 nm) out of 1605 
collected in two batches. Representative 2-D class averages of single particles 
(middle) and modelling of MmfR and the MARE1 DNA duplex into the cryo-EM 
density map using MDFF. e, Overall refined structure of the MmfR-MARE1 
complex. Two homodimers of MmfR (monomer units in green and blue) bind to 
opposite faces of MARE1 (backbone in yellow and bases in blue). The monomer 
units in one of the MmfR homodimers are labelled mA and mB, whereas in the 
other homodimer they are labelled mA' and mB'. HTH = DNA-binding helix-turn-
helix. The intra-dimer distance between DBDs was measured from the backbone 
nitrogen atoms of residue G64 in α-helix 3. f, View of the MmfR-MARE1 complex 
rotated 90º about the y axis. g, Overlay of the HBD domain C atoms for MmfR in 
complex with the hormone (pink) and MARE1 (green), highlighting the different 
conformational state adopted by MmfR in the two complexes. The inset shows the 
axis of -helix 1 tilts upwards by 40º in the MmfR-MMF2 complex relative to the 
MmfR-MARE1 complex, causing the HTH to pull away from the DNA major groove. 
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Fig. 3 | Insights into the mechanism of signal transduction in MmfR and other 
ArpA-like TFTRs. Highly conserved residues (in yellow) proposed to mediate 
signal transmission from the HBD to the DBD in TFTRs via a network of hydrogen 
bonding and hydrophobic interactions. The Y85 and Q130 residues connect the 
carboxyl group of the ligand (in cyan) to -helix 6 in AHFCA-binding TFTRs. 
Hydrogen bonding interactions and ordered water molecules are represented using 
dotted lines and purple spheres, respectively. The symbols (¥ and §) used to 
denote different residue types are defined in the legend for Extended Data Figure 
8a. 
17
Acknowledgements. C.C. acknowledges support of this work by a University 
Research Fellowship from The Royal Society (UF090255) and by grants 
BB/M022765/1 and BB/M017982/1 from the UK Biotechnology and Biological 
Sciences Research Council (BBSRC). G.L.C. is grateful to the Monash-Warwick 
Alliance (postdoctoral fellowship to H.B.), the University of Warwick (Chancellor’s 
International Scholarship to S.Z., Warwick Collaborative Postgraduate Research 
Scholarship to N.M. and Institute of Advanced Study Postdoctoral Research 
Fellowship to P.K.S.) and the ARC Centre of Excellence in Advanced Molecular 
Imaging for support of this work. Crystallographic data were collected at beam lines 
IO3, IO4 and I24 at Diamond Light Source, UK and we acknowledge the support 
of the beam line scientists. We thank Christopher J. Lupton for assisting with 
instrument set-up for the FA measurements and Ivan Prokes for assistance with 
acquiring the NMR data.   
Author contributions.  
C.C. designed the expression vector for MmfR. S.Z., K.M.S., G.L.C. and C.C. 
designed site-directed mutagenesis experiments. S.Z., P.J.H., G.L.C. and C.C 
designed the EMSA experiments. H.B. designed the FA experiments. S.Z., N.M. 
and G.L.C. designed the synthesis of the AHFCAs, analogues and SCB1. N.M., 
G.L.C. and C.C. designed the experiments to assess methylenomycin induction in
vivo using the library of AHFCAs and analogues. H.B., M.J.B., H.V. and G.L.C. 
designed cryo-EM experiments. 
S.Z., H.B., P.J.H., D.R. and C.C. overproduced and purified recombinant MmfR. 
S.Z. and L.S. performed protein MS analyses. S.Z. and K.M.S. created the MmfR 
18
mutants. S.Z. and N.M. synthesised the library of AHFCAs, analogues and SCB1. 
S.Z., P.J.H. and C.C. performed EMSAs. H.B. performed FA measurements. N.M. 
and C.C. investigated the in vivo activity of AHFCAs and analogues. D.R., P.K.S. 
and V.F. prepared samples for protein crystallisation, and D.R. and V.F. collected 
X-ray diffraction data. H.B. prepared samples for cryo-EM analysis and H.V. 
collected cryo-EM data. 
S.Z., H.B., N.M., P.J.H., G.L.C. and C.C. analysed the results of EMSAs. H.B. and 
G.L.C. analysed the results of FA measurements. D.R., HB and V.M. processed X-
ray diffraction data and solved protein structures. S.Z., D.R., H.B., L.M.A., V.F., 
G.L.C. and C.C. analysed the X-ray crystal structures. H.B., M.J.B. and H.V. 
processed cryo-EM data. H.B., M.J.B. and G.L.C. analysed the cryo-EM structure. 
S.Z., H.B., N.M., L.M.A., G.L.C. and C.C. wrote the manuscript with input from the 
other authors. 
Additional Information: 
Supplementary Information is available for this paper. 
Correspondence and requests for materials should be addressed to G.L.C. 
(G.L.Challis@warwick.ac.uk) or to C.C. (C.Corre@warwick.ac.uk). 
Reprints and permissions information is available at www.nature.com/reprints. 
G.L.C. discloses his role as a co-director of Erebagen Ltd; the other authors declare 
no competing interests. 
Data availability. The atomic coordinates have been deposited in the Protein Data 
Bank for apo and liganded MmfR under the accession numbers 7KY1 and 6SRN 
19
respectively. The three-dimensional cryo-EM map of protein-DNA complex has 
been deposited in the Electron Microscopy Data Bank (EMDB) under the accession 
number EMD-20781. This EMDB includes (1) raw half maps (2) B-factor sharpened 
map and (3) mask used for refinement and sharpening. 
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Extended Data Legends 
Extended Data Fig. 1 | Comparison of the mode of DNA and ligand binding, 
and mechanism of ligand-induced DNA release in TFTRs that regulate the 
expression of genes for antibiotic resistance and biosynthesis. For clarity, 
only -helices 1-3 forming the DNA-binding domain (DBD) in both repressor types, 
-helices 4 and 6 in the hormone binding domain (HBD) of the biosynthesis 
repressors and -helices 4, 6, 9 and 10 in the antibiotic binding domain (ABD) of 
the resistance repressors are shown in the schematics. The direction of movement 
of the DBD upon ligand binding is highlighted with an arrow. The distance between 
-helices 3 and 3' before and after DNA release and the distance between -helix 
1 and the ligand after release are given in Å. The structures of the 
antibiotics/hormones that act as ligands are shown and the name of the TFTR each 
bind to is shown in parentheses. a, TetR and SimR are examples of TFTRs that 
regulate antibiotic resistance. A single homodimer of these proteins binds the 
operator and the ligand binding site in the ABD is formed by residues from both 
subunits. b, MmfR as an example of a TFTR that regulates antibiotic biosynthesis. 
Two homodimers bind the operator and the ligand binding site in the HBD is formed 
by residues from only a single subunit. PDB entries for DNA form of TetR and SimR 
are 1QPI and 3QZL respectively and, their liganded entries are 2TRT and 2Y30 
respectively. 
Extended Data Fig. 2 | Confirmation of the purity and identity of recombinant 
MmfR and in vivo assay for induction of methylenomycin production in S. 
coelicolor. a, Analysis of purified recombinant His6-MmfR; left, SDS-PAGE (MWM: 
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molecular weight marker); right, mass spectrometry analysis: measured (top) and 
deconvoluted (bottom) mass spectra of His6-MmfR (calculated mass = 27835.5 
Da). b, In vivo assay for induction of methylenomycin production upon addition of 
increasing amounts of MMF1 signalling molecules to growing mycelia of the MMF 
non-producing strain S. coelicolor W81. Methylenomycin production was detected 
by growth inhibition of the methylenomycin-sensitive strain S. coelicolor M145. 
Extended Data Fig. 3 | EMSA data for release of wild type and mutant MmfR 
from the mmyB-mmyY and mmfL-mmfR intergenic regions in the presence 
of increasing quantities of the MMFs, MMF analogues and SCB1. a, Interaction 
of MmfR with DNA fragments corresponding to the mmyB-mmyY intergenic region 
(230 bp) in response to increasing amounts of MMFs. b, Interaction of MmfR with 
DNA fragments corresponding to the mmfL-mmfR intergenic region (194 bp) in 
response to increasing amounts of MMFs. c, Interaction of MmfR with the DNA 
fragments corresponding to the mmfL-mmfR intergenic region (194 bp) in response 
to increasing amounts of SCB1. d, EMSAs showing that Y85 and Q130 of MmfR 
play an important role in hormone-induced DNA release. Approximately ten times 
the quantity of MMF1 is required to release the Y85F and Q130E mutants of MmfR 
from the mmfL-mmfR intergenic region (194 bp) than the wild type protein. e, 
Interaction of MmfR with the DNA fragments corresponding to the mmfL-mmfR
intergenic region (194 bp) in response to increasing amounts of synthetic MMF 
analogues. Lane 1: isolated DNA fragments (0.1 pmol); lane 2: DNA fragments 
mixed with protein (0.1 pmol and 1.8 pmol respectively). For a, b and d, lanes 3 to 
9: addition of increasing quantities of MMFs (0.8, 4, 8, 14, 20, 40 and 100 nmol 
respectively) to the protein-DNA complexes. For c, lanes 3 to 7: addition of 
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increasing quantities of racemic SCB1 (0.8, 8, 20, 40 and 400 nmol respectively) 
to the DNA/protein complexes. For e, lanes 3 to 6: addition of increasing quantities 
of MMF analogues (0.8, 8, 20 and 100 nmol respectively) to the DNA/protein 
complexes. At least two independent technical replicates of each EMSA were 
conducted and in all cases similar results were obtained. For gel source data, see 
Supplementary Figure 1a-d. 
Extended Data Fig. 4 | Results of FA measurements and EMSAs showing that 
MmfR binds MAREs in the mmfL-mmfR and mmyB-mmyY intergenic regions 
and is released from the MAREs by the MMFs. a, Fluorescence anisotropy plots 
for binding of MmfR to DNA duplexes containing MARE1 and MARE2. Data points 
are the mean of three independent technical replicates and error bars represent 
the standard deviations from the mean. The Kd (nM) and Hill coefficient (ƞ) 
calculated from each data set are shown. The structure of the DNA duplex used in 
each experiment is shown below the plot.  b, Confirmation from EMSAs that the 
five naturally occurring MMFs are able to release MmfR from the mmfL-mmfR and 
mmyB-mmyY intergenic regions, and EC50 values calculated from FA 
measurements for release of MmfR from DNA duplexes containing MARE1 and 
MARE2. 
Extended Data Fig. 5 | Synthetic routes for MMFs and analogues and SCB1. 
a, Synthetic route to SCB1. b, General synthetic route to MMFs and most 
analogues. c, Synthetic route for MMF analogue 1 lacking a 2-alkyl group. 
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Extended Data Fig. 6 | Electron density map for MMF2 bound to MmfR, 
comparison of the overall fold of the MmfR and CprB monomers and X-ray 
crystal structures of TFTR-operator complexes. a, SIGMAA-weighted mFo-Fc 
electron density omit map for MMF2 bound to MmfR in mesh representation 
contoured at the 5 level. b, Overall fold of the MmfR monomer. c, Overall fold of 
the CprB monomer (PDB ID: 4PXI). Both structures are colour-ramped from blue 
to red from the N- to C-terminus. d, X-ray crystal structures of TFTRs that bind as 
pairs of homodimers in complex with their operators. PDB IDs are as follows: 6EN8 
(SaFadR), 6C31 (Rv0078), 4JL3 (Ms6564), 5GPC (FadR), 1JT0 (QacR), 4I6Z 
(TM1030), 2YVH (CgmR), 4PXI (CprB), 5VL9 (EilR) and 4GCT (SlmA). e, X-ray 
crystal structures of TFTRs that bind as single homodimers in complex with their 
operators. PDB IDs are as follows: 1QPI (TetR), 5DY0 (AmtR), 3LSP (DesT), 5UA1 
(KstR), 3ZQL (SimR), 5K7Z (AibR), 3VOK (HrtR) and 5YEJ (BioQ). f, Side view of 
the QacR- and CprB-operator complexes highlighting the obtuse angle between 
the planes that bisect the monomers in each homodimer.
Extended Data Fig. 7 | Data quality, overall view of model and cryo-EM map 
fit for the MmfR-MARE1 complex. a, Relion corrected Fourier shell correlation 
(FSC) curve of protein-DNA complex map. The inset shows the angular distribution 
of the particle projections. The length of the projection is a direct measure of the 
number of assigned particles in each direction. b, Model construction by fitting the 
coordinates for the MmfR-MMF2 complex (pink and blue cartoon) into the cryo-EM 
density map. Different views of the cryo-EM density maps with the protein-DNA 
complex modelled into it are shown to the right. c, Zoomed-in view of the DBD 
showing how differently it is oriented in the MmfR-MMF2 complex compared to the 
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MmfR-MARE1 complex. d, Local resolution values projected onto the experimental 
density map. 
Extended Data Fig. 8 | Sequence alignment of MmfR with other ArpA-like 
TFTRs and structural mapping of conserved residues. a, Multiple sequence 
alignment of TFTRs of known hormone specificity. Amino acids showing a high 
degree of conservation are coloured yellow, whereas those showing a low degree 
of conservation are coloured grey. Highly conserved residues hypothesised to be 
involved in the signal transmission from -helices 4 and 6, through -helix 1 to -
helices 2 and 3 in all TFTRs are marked ¥. The highly conserved residues and 
residue (F182), which is only conserved in AHFCA-binding TFTRs, lining the 
hydrophobic pocket of the HBD are indicated with  and £, respectively. The Y85 
and Q130 residues, universally conserved in AHFCA-binding TFTRs, are marked 
§. Protein names are coloured according to the type of ligand each TFTR responds 
to; cyan: AHFCAs, red: GBLs, purple: AHMBs and blue: ABs. b, Mapping of 
residues showing a high (yellow) and low (grey) degree of conservation onto the 
structure of the MmfR-MMF2 complex. 
Extended Data Table 1 | Induction of methylenomycin production by MMFs 
and analogues, and SCB1 in S. coelicolor. The ability of the five naturally 
occurring MMFs, the synthetic MMF analogues and SCB1 to induce production of 
methylenomycin A was compared by observing growth inhibition of 
methylenomycin-sensitive S. coelicolor M145 around agar plugs containing MMF 
non-producing S. coelicolor W81 and five different concentrations of each inducer. 
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Extended Data Table 2 | Results of EMSA and FA experiments to probe the 
role of hormone functional groups in DNA release using an MMF analogue 
library. Structural alterations to the alkyl chain included shortening (analogues 1-
4), lengthening (analogues 5 and 6), desaturation (analogue 7), altering the 
position of the methyl branch (analogue 8) and incorporation of an oxygen atom 
(analogue 9). The carboxylic acid group was converted to the corresponding methyl 
ester (analogue 10) and the hydroxymethyl group was replaced with a methyl group 
(analogue 11) or a hydrogen atom (analogue 12). Note: ++, DNA release observed 
with compound at 8 nmol and above; +, DNA release observed with compound at 
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Strains and plasmids  
The strains and plasmids used in this study are summarized in Supplementary Table 1. 
Gene cloning 
The mmfR gene (UniProt ID: Q9JN89) was amplified from cosmid C73_787 by PCR using the primers 
listed in Supplementary Table 2. A CACC sequence was introduced at the 5'-end of the forward primer 
to allow for directional cloning of the blunt-ended PCR products into pET151/D-TOPO, resulting in the 
fusion of hexahistidine tag to the N-terminus of the recombinant protein. PCR products were purified 
using the GeneJET Gel Extraction kit (Thermo Scientific) and ligated with the linearized expression 
vector using the Champion pET151 Directional TOPO Expression kit (Invitrogen) according to the 
manufacturer’s guidelines. One Shot TOP10 chemically competent E. coli cells were transformed with 
the TOPO cloning reaction mixture. Transformants were selected on LB agar plates supplemented with 
ampicillin (100 μg/mL). Plasmids were purified from ampicillin-resistant colonies using the GeneJET 
Plasmid Miniprep kit and the integrity of the cloned gene was confirmed by sequencing (GATC Biotech).  
Protein overproduction and purification 
For crystallization and EMSAs, recombinant His6-MmfR was overproduced in E. coli BL21 Star (DE3) 
cells carrying the pET151-mmfR plasmid. Cells were cultured in LB medium containing 100 g/mL 
ampicillin at 37 ºC to an OD600 of ~0.6. Expression was induced with 1 mM IPTG, and growth was 
continued at 20 ºC overnight. Cells were harvested by centrifugation, resuspended in binding buffer A 
(20 mM HEPES, 0.5 M NaCl, 10% glycerol, 10 mM imidazole, pH 8), lysed by sonication, and clarified 
by centrifugation for 30 min at 4 ºC. Cell lysates were passed through a 5 mL chelating sepharose FF 
column (GE Healthcare) charged with nickel and equilibrated in binding buffer. The column was washed 
with 100 mL binding buffer A, then 100 mL binding buffer containing 100 mM imidazole, and the protein 
was eluted in binding buffer containing 500 mM imidazole. Eluted protein was concentrated using a 
centrifugal concentrator with a 10,000 molecular weight cut-off (Vivaspin), and further purified by gel 
filtration chromatography on a Superdex S-200 column (GE Healthcare) equilibrated in buffer B (20 mM 
Tris-HCl, pH 8, 200 mM NaCl). Eluted protein was buffer-exchanged into buffer C (20 mM Tris-HCl, pH 
8.0) and concentrated to 14 mg/mL using a centrifugal concentrator, frozen in aliquots of 100 L in 
liquid nitrogen, and stored at -80 ºC. 
The same procedure was used to produce MmfR for cryo-EM analysis, except for the following. 
IPTG induction was carried out at 18 ºC; the protein was purified on a Ni2+‐nitrilotriacetic acid (Ni-NTA) 
sepharose resin (GE Healthcare), eluting with a linear gradient of imidazole (100 – 400 mM) in buffer 
A; and gel filtration was carried out on a HiPrep 16/60 Sephacryl S-200 HR column (GE Healthcare). 
The hexahistidine tag was removed by adding 1 mg/mL of purified recombinant His6-Tobacco Etch 
Virus protease to 10 mg/mL of MmfR and incubating at 20 C for 12 h in buffer B containing 0.1 mM 
EDTA and 0.2 mM DTT21. The reaction mixture was passed through Ni-NTA resin equilibrated in buffer 
B to separate the His6-TEV protease from the cleaved MmfR protein. The flow through was further 
purified by gel filtration on a HiPrep 16/60 Sephacry S-200 HR column equilibrated in buffer B. The 
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eluted protein was concentrated to 27 mg/mL using a 10,000 molecular weight cut-off centrifugal 
concentrator (Vivaspin).  
Protein crystallisation and X-ray data collection 
Conditions for the crystallization of purified recombinant His6-MmfR were screened using a Honeybee 
crystallization robot. Sitting drops contained 200 nL of 14 mg/mL His6-MmfR and 200 nL reservoir 
solution. Reservoirs contained 75 L of reservoir solution. Numerous hits were obtained and the best 
crystals grew in a solution containing 20% PEG 3,350 and 0.2 M of various divalent cations. Following 
optimization in hanging drops containing 1 L protein and 1 L reservoir solution, X-ray diffraction-
quality crystals were grown in 10-15% PEG 3,350 and 0.2-0.25 M magnesium formate. Crystals were 
removed from sitting drops using a nylon loop, soaked briefly in LV cryo oil (MiTeGen), frozen and 
stored in liquid nitrogen. Crystals diffracted to 1.9 Å in-house using a sealed tube X-ray generator, and 
to 1.5 Å using synchrotron radiation at Diamond Light Source on beam line I24 (UK). 
Purified recombinant His6-MmfR (14 mg/mL) was mixed with 1 mM MMF2 and the resulting mixture 
was subjected to the crystallization conditions described above. These crystals also diffracted to 1.5 Å, 
using synchrotron radiation at Diamond Light Source on beam line IO4. 
Selenomethionine-labelled protein was prepared by overproducing His6-MmfR in the methionine 
auxotroph E. coli B834 as described above, except minimal medium containing selenomethionine 
instead of methionine was used. The resulting protein was purified as described above, except 5 mM 
2-mercaptoethanol was included in all purification buffers, and crystallized in several conditions, with 
the best crystals grown in a solution containing 8% PEG 8,000, 0.1 M magnesium acetate and 0.1 M 
sodium acetate, at pH 4.5. These crystals diffracted to 2 Å using synchrotron radiation at Diamond Light 
Source, and a complete dataset was collected at the peak following a wavelength scan at beam line 
IO3. 
X-ray data processing, structure determination and refinement 
All X-ray diffraction data were processed using XDS22. Further data handling was carried out using the 
CCP4 software package23. The structure was phased using only peak wavelength data from 
selenomethionine-labelled His6-MmfR crystals using a single-wavelength anomalous dispersion (SAD) 
approach. The SOLVE program located all seven selenated sites in the protein, and RESOLVE fitted 
52% of the residues in the resulting electron density24,25. At this stage, model building was continued 
on the 1.5 Å data set from the isomorphous MmfR-MMF2 complex, and the model was further extended 
automatically by ARP and manually using O26,27. The unliganded structure was solved by molecular 
replacement using Phaser28. We employed the standard maximum likelihood restrained refinement with 
TLS and isotropic B factors for both structures using REFMAC529. Water molecules were added to the 
atomic models automatically using ARP at the positions of large positive peaks in the difference electron 
density map, only where the resulting water molecule fell into an appropriate hydrogen bonding 
environment. The unliganded structure was further refined in Phenix with TLS and isotropic B factors, 
and maximum likelihood and X-ray/stereochemistry weight restraints, in addition to the default 
refinement parameters and water molecules were added using phenix.refine30 and manual refinement 
done in COOT31. The crystallographic asymmetric unit contains one subunit of the polypeptide chain in 
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both structures. The structures of the dimers were generated from the crystallographic two-fold 
symmetry operators. The polypeptide could be unambiguously traced from residues 26-214 and 28-
214 in the unliganded and MmfR-MMF2 complex structures, respectively. Data collection and 
refinement statistics are given in Supplementary Table 3. 
Cryo-Electron Microscopy  
The protein-DNA complex was prepared by adding annealed MARE1 oligonucleotide (5'-
ATACCTGCGGGAAGGTATT-3') to a 0.5-fold molar excess of cleaved MmfR and incubating at 20 C 
for 1 h. It was purified by gel filtration using the column and protocol described above for cleaved MmfR 
and concentrated to 17.0 mg/mL. The MmfR-MARE1 complex was diluted to a concentration of 0.1 
mg/mL in buffer B and the resulting solution was spotted onto plasma-cleaned QUANTIFOIL Cu EM 
grids (hole size R1.2/1.3), which were plunge frozen in liquid ethane using an FEI Vitrobot Mark III 
(blotting time 3.0 s, 100% humidity, −3 mm blotting force, drain time 1 s at 4 C). Cryo-EM micrographs 
were collected using Thermo Fisher Scientific Titan Krios™ equipped with a Gatan K2 Summit™ with 
Quantum-GIF energy filter operated at 300 kV at zero loss mode. A condenser aperture of 50 micron 
and FEI Voltage phase plate was used in the objective plane. Two Cryo-EM movie datasets (725 and 
880 micrographs, each micrograph containing 50 frames) with 10 s exposure time and a total dose of 
50 electrons per Å2 were recorded in counting mode at a nominal magnification of 165,000 (EFTEM 
mode), which corresponds to a calibrated pixel size of 0.84 Å. Thermo Fisher Scientific EPU automated 
data collection software was used for data acquisition. Autofocus was set to keep the defocus at 0.5 
micron and the phase plate position was advanced every hour.  
The acquired movie frames were corrected for beam-induced translational motion and summed 
using MotionCor2 (version 2.1.10-cuda8.0) and the pixel size was raised to 1.092 Å by binning the 
dataset32. The summed images were saved and subjected to contrast transfer function (CTF) estimation 
employing GCTF (version 1.06-cuda8)33. Summed images with the best CTF fit, phase estimation and 
a defocus inside the range of 0.5–3.0 micron were selected manually by inspecting the thon rings fit to 
the theoretical resolution shells and these micrographs were retained for further image processing. This 
procedure resulted in datasets of 675 and 770 micrographs for MmfR-MARE1 complex. Subsequently, 
the micrographs were subjected to particle picking using crYOLO1.1334. One hundred images were 
chosen randomly and about 3,000 particles were picked manually to train the auto-picking module, 
which was then used to auto-pick particles from the CTF corrected and retained summed images of the 
complex. The trained module was able to pick 181,409 and 292,512 well-centred particles for the 
complex at a box size of 140 Å (Supplementary Table 4). The particles were then extracted and 
combined for initial 2-D classification in cryoSPARC35 (v2) and later a reference-free 2-D classification 
in Relion3.036 to filter out low-quality particles. This yielded a total of 379,033 particles, which were 
extracted at a box size of 180 pixels and a pixel size of 1.092 Å. The extracted particles were 3-D 
classified and an initial 3-D model was generated in Relion. From the 2-D and 3-D classes, it appeared 
that the complex has no symmetry. Thus, C1 symmetry was applied for all the model refinement steps 
and the particle size was not changed during data reduction and refinement. The particles resulting 
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from tight masking and model refinement yielded an overall resolution of 4.2 Å with good angular 
distribution (Extended Data Figure 7).  
Modelling of the protein-DNA complex 
The X-ray crystal structure of unliganded MmfR was manually aligned with the cryo-EM density map 
using Chimera37. MmfR was found to adopt four distinct positions in the map. B-form MARE1 DNA was 
also manually docked into the cryo-EM density map. The models were combined and the fit was 
optimised using molecular dynamics flexible fitting (MDFF) using namd2/MDFF38. Runs were prepared 
with the VMD39 graphical user interface, and NAMD40 was used with the correction map and the 
CHARMM3641,42 force field to perform the MDFF. Figures were rendered in Chimera and PyMol 
(http://www.pymol.org). 
Fluorescence anisotropy measurements 
One strand from each MARE-containing duplex was 5'-fluorescently labelled with 6-carboxyfluorescein 
(FAM) and annealed in 5 mM Tris pH 7.5, 15 mM NaCl 0.1 mM EDTA, pH 8.0 (100 μM final 
concentration) with a complementary unlabelled oligonucleotide by heating to 95 °C for 5 min and slowly 
cooling to room temperature43. The resulting duplexes were used in steady-state FA titrations to assess 
wild type and mutant MmfR binding and subsequently release by the MMFs and synthetic analogues. 
Ligands were dissolved in DMSO (200 mM) and the resulting solutions were diluted to 0.1% using buffer 
B. All titration experiments were carried out at ambient temperature on a Horiba (Jobin Vyon) – 
FluoroMax-4 spectrofluorometer. FAM-labelled duplexes were excited at wavelength 485 nm and 
emission was recorded at 520 nm (em). Both excitation and emission slit widths were set at 4 nm. The 
path length was 1 cm and the signal integration time was set as 0.15 s. Each sample was measured in 
500 L total volume of buffer B. The final DNA concentration was 10 nM for all measurements and the 
protein concentration was 100 nM for the DNA release measurements. There was no detectable 
intrinsic fluorescence of buffering components at em. Samples were equilibrated for 5 min after addition 
of titrant before the change in FA was measured. Experiments were performed in triplicate and 
anisotropy values were calculated using Supplementary equation 1. The apparent Kd and Hill coefficient 
(ƞ) were determined by plotting the mean FA values against log[protein/small molecule] and the 
resulting binding isotherms were fitted using non-linear regression to Supplementary equation 2 using 
Origin 7.0. Error bars represent the standard deviations from the mean and the level of confidence in 
the curve fitting was 97-100%. The G-factor was determined using a solution of free fluorescein. 
Electrophoretic mobility shift assays 
The mmfL-mmfR (194 bp) and mmyB-mmyY (230 bp) intergenic DNA sequences containing the 
proposed binding sites for MmfR were amplified from cosmid C73_787 by PCR using the primers shown 
in Supplementary Table 2. The EMSAs were run on 6% non-denaturing polyacrylamide gels. In each 
EMSA, lane 1 contained 0.1 pmol of DNA fragment only and other lanes contained 0.1 pmol of DNA 
and 1.8 pmol of protein. From lane 3, increasing concentrations of compound, which was dissolved in 
DMSO, were added. The specific amount of each compound used was listed in the legend of the 
corresponding figure. For each 20 μL reaction, 4 μL of 5 binding buffer (100 mM HEPES, 50 mM 
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(NH4)2SO4, 150 mM KCl, 5 mM EDTA, 5 mM DTT, 1% (w/v) Tween 20, pH 7.6) was used. DNA, protein, 
5 binding buffer and distilled water were first mixed and incubated at room temperature for 15 min. 
After addition of compound solution, the resulting mixture was incubated at room temperature for 10 
min, and 5 μL of loading buffer, containing 0.25 TBE, 34% (v/v) glycerol and 0.2% (w/v) bromophenol 
blue, were added. The total volume of each reaction did not exceed 25 μL. Samples were separated 
with a pre-run native polyacrylamide gel in 1 TBE buffer at 80 V at 4 °C until the loading dye had 
migrated to the bottom of the gel. On completion, the gel was incubated in a solution of GelRed (0.005% 
v/v) in 1 TBE buffer at room temperature for 30 min with agitation, then visualised on a UV 
transilluminator.  
Induction of methylenomycin production 
As described previously, we added solutions of each compound at various concentrations directly to 
round plugs of AlaMM agar (pH 5.0, allowing optimal diffusion of methylenomycin) with 2-day old 
cultures of S. coelicolor W81 (MMF non-producer) growing on them3. Each compound was 
resuspended in methanol at diverse concentrations so that adding a 10 μL volume to the plug resulted 
in quantities of compounds ranging from 0.01 to 50 μg. The plugs were placed on an agar plate 
inoculated with S. coelicolor M145 (SCP1-, SCP2-, methylenomycin-sensitive) and, after 96-120 h of 
incubation at 30 °C, the extent of growth inhibition around the plugs (resulting from methylenomycin 
production) was recorded. 
Site-directed mutagenesis 
The Q130E, Y85F and Y144F mutants of His6-MmfR were created using the Q5 Site-Directed 
Mutagenesis Kit (New England Biolabs) according to the manufacturer’s instructions. The primers used 
are listed in Supplementary Table 2. All constructs were sequenced to confirm the presence of the 
desired mutations. 
Synthesis of MMFs and their analogues and SCB1 
General experimental details 
Anhydrous toluene, tetrahydrofuran (THF), N,N-dimethylformamide (DMF) and dichloromethane (DCM) 
were obtained by distillation from calcium hydride under argon and stored over activated 4 Å molecular 
sieves. All other reagents and solvents were used as supplied (Sigma-Aldrich, VWR or Fisher Scientific). 
Flash column chromatography was conducted on Sigma-Aldrich silica gel (40-63 μm, 60 Å). Thin layer 
chromatography (TLC) was carried out on aluminium backed sheets pre-coated with Merck silica gel 
60 F254 and visualised by UV radiation, phosphomolybdic acid or potassium permanganate. The 1H- 
and 13C-NMR spectra were obtained using a Bruker DPX 300, DPX 400 or Avance III HD 500 MHz 
spectrometer. Chemical shifts (δ) are given in ppm with reference to the residual solvent peak. Coupling 
constants (J) are rounded to the nearest 0.5 Hertz (Hz). Multiplicities are given as multiplet (m), singlet 
(s), doublet (d), triplet (t), quartet (q), quintet (quin), sextet (sext), septet (sept) and nonet (non). Low 
resolution ESI mass spectra were recorded using an Agilent 6130B single quadrupole spectrometer. 
High resolution mass spectra (HRMS) were recorded on a Bruker MaXis impact mass spectrometer.  
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Synthesis of MMFs and analogues 
Most of the MMFs and analogues with alteration to the alkyl chains were synthesized according to 
literature procedures44,45. The general synthetic route is shown in Extended Data  Figure 5b. It includes 
preparation of the desired β-ketoester44, and subsequent scandium triflate-catalysed condensation with 
the desired ketone prepared according to published literatures: dihydroxyacetone acetonide46, 
hydroxylacetone, hydroxyacetaldehyde, 1-amino-3-hydroxypropan-2-one47 or mercaptopropanone48.  
MMF analogue 10 is the methyl ester intermediate during MMF1 synthesis. The NMR spectra of MMFs 
1-5 and analogue 10 are identical to the reported data45. The MMF analogue 1 without an alkyl chain 
was produced using a reported method of mono-hydrolysis of the di-ester starting material by dilute 
reaction condition followed by selective reduction of the ester group in Extended Data  Figure 5c49,50.  
General procedure for synthesis of β-ketoesters 
Thionyl chloride (2 eq.) and a catalytic amount of DMF were slowly added to starting acid (1 eq.) under 
argon. The mixture was stirred overnight at room temperature. The volatile material was removed in 
vacuo using a sodium hydroxide trap. The resulting crude material was used without further purification. 
To a 0.5 M solution of Meldrum’s acid (1 eq.) in dry DCM under argon, dry pyridine (2 eq.) and 4-
dimethylaminopyridine (0.2 eq.) were added and the mixture was stirred for 10 min at room temperature 
before being cooled to 0 °C. Then 1 eq. of the desired acid chloride (or the previous crude mixture) was 
added dropwise and the reaction was warmed to room temperature and stirred overnight. The resulting 
mixture was washed with 1 M HCl and water. The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. The resulting dark-yellow oil was diluted in methanol to a final concentration of 
0.5 M. The reaction was refluxed for 5 h before the solvent was removed in vacuo. The oil residue was 
purified by flash chromatography (pentane/diethyl ether = 6:1 v/v) to afford the desired β-ketoester as 
a pale yellow oil.  





Yield: 60%. 1H NMR (400 MHz, CDCl3) δ: 0.83 (d, J = 6.5 Hz, 6H), 2.05 (m, 1H), 2.32 (d, J = 7.0 Hz, 
2H), 3.35 (s, 2H), 3.63 (s, 3H). 13C NMR (100 MHz, CDCl3) δ: 202.3, 167.6, 52.1, 51.7, 49.3, 24.2, 22.3. 




Yield: 55%. 1H NMR (400 MHz, CDCl3) δ: 0.92 (t, J = 7.5 Hz, 3H), 1.61 (sext, J = 7.5 Hz, 2H), 2.54 (t, J 
= 7.5 Hz, 2H), 3.47 (s, 2H), 3.71 (s, 3H). 13C NMR (100 MHz, CDCl3) δ: 202.5, 167.5, 51.8, 48.6, 44.4, 






Yield: 21%. 1H NMR (400 MHz, CDCl3) δ: 0.83 (d, J = 6.0 Hz, 6H), 1.54 (m, 3H), 2.54 (m, 2H), 3.48 (s, 
2H), 3.73 (s, 3H). 13C NMR (100 MHz, CDCl3) δ: 202.9, 179.9, 167.8, 40.9, 33.4, 32.0, 27.4, 22.1. HR-




Yield: 80%. 1H NMR (400 MHz, CDCl3) δ: 0.89 (t, J = 7.5 Hz, 3H), 1.29 (m, 4H), 1.57 (br quin, J = 7.5 
Hz, 2H), 2.54 (t, J = 7.5 Hz, 2H), 3.46 (s, 2H), 3.69 (s, 3H). 13C NMR (100 MHz, CDCl3) δ: 202.3, 167.4, 





Yield: 38%. 1H NMR (400 MHz, CDCl3) δ: 1.04 (d, J = 7.0 Hz, 6H), 2.65 (sept, J = 7.0 Hz, 1H), 3.45 (s, 
2H), 3.63 (s, 3H). 13C NMR (100 MHz, CDCl3) δ: 206.3, 197.7, 51.9, 46.7, 40.9, 17.6. HR-MS: m/z 




Yield: 30%. 1H NMR (400 MHz, CDCl3) δ: 0.88 (m, 3H), 1.29 (m, 6H), 1.61 (m, 2H), 2.54 (t, J = 7.5 Hz, 
2H), 3.46 (s, 2H), 3.72 (s, 3H). 13C NMR (100 MHz, CDCl3) δ: 202.8, 167.7, 52.03, 48.7, 42.8, 31.4, 




Yield: 85%. 1H NMR (400 MHz, CDCl3) δ: 0.81 (t, J = 7.0 Hz, 3H), 1.22 (m, 8H), 1.53 (m, 2H), 2.47 (t, J 
= 7.5 Hz, 2H), 3.39 (s, 2H), 3.67 (s, 3H). 13C NMR (100 MHz, CDCl3) δ: 202.9, 167.7, 52.2, 49.0, 43.0, 








Yield: 51%. 1H NMR (400 MHz, CDCl3) δ: 2.17 (m, 2H), 2.50 (m, 2H), 3.31 (m, 2H), 3.56 (m, 3H), 4.86 
(m, 2H), 5.64 (m, 1H). 13C NMR (100 MHz, CDCl3) δ: 201.7, 167.4, 136.5, 115.3, 51.9, 48.7, 41.7, 27.2. 




Yield: 34%. 1H NMR (400 MHz, CDCl3) δ: 0.73 (m, 3H), 0.94 (m, 3H), 1.26 (m, 1H), 1.54 (m, 1H), 2.42 
(m, 1H), 3.35 (s, 2H), 3.55 (s, 3H). 13C NMR (100 MHz, CDCl3) δ: 206.2, 167.7, 51.9, 47.8, 47.2, 25.3, 
15.1, 11.1. HR-MS: m/z calculated for C8H14O3 [M+Na]+: 181.0843; found: 181.0843.  
 
General procedure for furan cyclisation  
The desired ketone (1 eq.) and β-ketoester (1 eq.) were dissolved in methanol to obtain a 0.5 M solution. 
Scandium III triflate (0.1 eq.) was added and allowed to stir overnight at room temperature. The solvent 
was removed in vacuo and the residue was purified by flash chromatography (pentane/diethyl ether = 
4:1 v/v) giving the desired furan as a pale yellow oil. 
 
Methyl 4-(hydroxymethyl)-2-isobutylfuran-3-carboxylate (MMF analogue 10) 
 
Yield: 76%. 1H NMR (400 MHz, CDCl3) δ: 0.91 (d, J = 6.5 Hz, 6H), 2.04 (m, 1H), 2.81 (d, J = 7.0 Hz, 
2H), 3.82 (s, 3H), 4.20 (br s, 1H), 4.58 (s, 2H), 7.27 (s, 1H). 13C NMR (100 MHz, CDCl3) δ: 165.1, 163.6, 
138.3, 126.0, 112.2, 55.8, 51.1, 36.5, 28.1, 22.1. HR-MS: m/z calculated for C11H16O4 [M+Na]+: 




Yield: 84%. 1H NMR (400 MHz, CDCl3) δ: 0.94 (t, J = 7.5 Hz, 3H), 1.68 (sext, J = 7.5 Hz, 2H), 2.91 (t, J 
= 7.5 Hz, 2H), 3.85 (s, 3H), 3.91 (br s, 1H), 4.56 (s, 2H), 7.25 (s, 1H).  13C NMR (100 MHz, CDCl3) δ: 
165.4, 164.5, 138.3, 125.9, 111.9, 55.8, 51.4, 29.9, 21.2, 13.6. HR-MS: m/z calculated for C10H14O4 






Yield: 83%. 1H NMR (400 MHz, CDCl3) δ: 0.92 (d, J = 6.0 Hz, 6H), 1.54 (m, 3H), 2.81 (t, J = 7.5 Hz, 
2H), 4.13 (br s, 1H), 3.82 (s, 3H), 4.56 (s, 2H), 7.24 (s, 1H). 13C NMR (100 MHz, CDCl3) δ: 165.1, 164.6, 
138.1, 126.1, 111.4, 55.8, 51.1, 36.7, 27.5, 25.9, 23.0. HR-MS: m/z calculated for C12H18O4 [M+Na]+: 




Yield: 80%. 1H NMR (400 MHz, CDCl3) δ: 0.92 (t, J = 7.5 Hz, 3H), 1.35 (sext, J = 7.5 Hz, 2H), 1.63 (quin, 
J = 7.5 Hz, 2H), 2.94 (t, J = 7.5 Hz, 2H), 3.85 (s, 3H), 3.91 (br s, 1H), 4.56 (s, 2H), 7.24 (s, 1H). 13C 
NMR (100 MHz, CDCl3) δ: 165.4, 164.7, 138.2, 125.9, 111.8, 55.8, 51.4, 29.9, 27.7, 22.2, 13.6. HR-MS: 




Yield: 76%. 1H NMR (400 MHz, CDCl3) δ: 0.89 (t, J = 7.0 Hz, 3H), 1.35 (m, 4H), 1.66 (q, J = 7.5 Hz, 
2H), 2.93 (t, J = 7.5 Hz, 2H), 3.85 (s, 3H), 3.87 (br s, 1H), 4.56 (s, 2H), 7.24 (s, 1H). 13C NMR (100 MHz, 
CDCl3) δ: 165.4, 164.7, 138.2, 125.9, 111.8, 55.8, 51.4, 31.2, 28.0, 27.5, 22.2, 13.8.  HR-MS: m/z 
calculated for C12H18O4 [M+Na]+: 249.1097; found: 249.1097.  
 
tert-Butyl 4-(hydroxymethyl)-2-methylfuran-3-carboxylate  
 
Yield: 68%. 1H NMR (400 MHz, CDCl3) δ: 1.47 (s, 9H), 2.40 (s, 3H), 4.01 (br s, 1H), 4.43 (s, 2H), 7.09 
(s, 1H). 13C NMR (100 MHz, CDCl3) δ: 164.6, 160.0, 137.7, 126.1, 113.9, 81.5, 55.8, 28.2, 14.3. HR-








Yield: 85%. 1H NMR (400 MHz, CDCl3) δ: 1.22 (t, J = 7.5 Hz, 3H), 2.95 (q, J = 7.5 Hz, 2H), 3.84 (s, 3H), 
4.15 (br s, 1H), 4.56 (s, 2H), 7.25 (s, 1H). 13C NMR (100 MHz, CDCl3) δ: 165.3, 165.0, 138.2, 126.0, 




Yield: 79%. 1H NMR (400 MHz, CDCl3) δ: 1.25 (d, J = 7.0 Hz, 6H), 3.69 (sept, J = 7.0 Hz, 1H), 3.77 (br 
s, 1H), 3.86 (s, 3H), 4.56 (s, 2H), 7.25 (s, 1H). 13C NMR (100 MHz, CDCl3) δ: 168.5, 165.5, 138.2, 125.8, 




Yield: 40%. 1H NMR (400 MHz, CDCl3) δ: 0.79 (m, 3H), 1.21 (m, 6H), 1.66 (m, 2H), 2.83 (t, J = 7.5 Hz, 
2H), 3.76 (s, 3H), 3.86 (br s, 1H), 4.47 (s, 2H), 7.14 (s, 1H). 13C NMR (100 MHz, CDCl3) δ: 165.4, 164.6, 
138.2, 125.7, 111.8, 55.6, 51.5, 31.4, 28.4, 27.9, 22.5, 13.7. HR-MS: m/z calculated for C13H20O4 




Yield: 70%. 1H NMR (400 MHz, CDCl3) δ: 0.86 (t, J = 7.0 Hz, 3H), 1.27 (m, 8H), 1.62 (m, 2H), 2.90 (t, J 
= 7.5 Hz, 2H), 3.70 (br s, 1H), 3.85 (s, 3H), 4.53 (s, 2H), 7.22 (s, 1H). 13C NMR (100 MHz, CDCl3) δ: 
165.8, 165.0, 138.4, 129.9 112.1, 55.8, 51.8, 31.8, 29.2, 29.0, 28.3, 28.0, 22.7, 14.2. HR-MS: m/z 








Yield: 82%. 1H NMR (400 MHz, CDCl3) δ: 2.41 (q, J = 7.5 Hz, 2H), 3.04 (t, J = 7.5 Hz, 2H), 3.70 (br s, 
1H), 3.87 (s, 3H), 4.56 (s, 2H), 4.98 (dd, J = 10.5 and 1.5 Hz, 1H), 5.04 (dd, J = 17.0 and 1.5 Hz, 1H), 
5.82 (dddd, J = 17.0, 10.0, 6.5 and 6.5 Hz, 1H),7.25 (s, 1H). 13C NMR (100 MHz, CDCl3) δ: 165.5, 163.7, 
138.5, 136.9, 125.9, 115.5, 112.3, 55.8, 51.7, 31.9, 27.8. HR-MS: m/z calculated for C11H14O4 [M+Na]+: 




Yield: 68%. 1H NMR (400 MHz, CDCl3) δ: 0.72 (t, J = 7.5 Hz, 3H), 1.12 (d, J = 7.5 Hz, 3H), 1.55 (quin, 
J = 7.0 Hz, 2H), 3.41 (sext, J = 7.0 Hz, 1H), 3.74 (s, 3H), 3.87 (br s, 1H), 4.47 (s, 2H), 7.17 (s, 1H). 13C 
NMR (100 MHz, CDCl3) δ: 166.7, 164.6, 137.4, 124.9, 110.6, 55.0, 50.5, 33.3, 27.4, 17.5, 10.9. HR-MS: 




Yield: 75%. 1H NMR (400 MHz, CDCl3) δ: 3.22 (m, 2H), 3.32 (s, 3H), 3.66 (m, 2H), 3.84 (s, 3H), 4.10 
(br s, 1H), 4.57 (s, 2H), 7.30 (s, 1H). 13C NMR (100 MHz, CDCl3) δ: 164.8, 160.9, 138.8, 126.2, 112.6, 




Yield: 59%. 1H NMR (400 MHz, CDCl3) δ: 0.91 (d, J = 6.5 Hz, 6H), 2.05 (non, J = 6.5 Hz, 1H), 2.13 (s, 
3H), 2.82 (d, J = 7.0 Hz, 2H), 3.79 (s, 3H), 7.04 (s, 1H), 13C NMR (100 MHz, CDCl3) δ: 164.8, 163.2, 









Yield: 75%. 1H NMR (400 MHz, CDCl3) δ: 0.93 (d, J = 6.5 Hz, 6H), 2.08 (non, J = 6.5 Hz, 1H), 2.88 (d, 
J = 7.0 Hz, 2H), 3.81 (s, 3H), 6.64 (s, 1H), 7.25 (s, H). 13C NMR (100 MHz, CDCl3) δ: 164.5, 162.7, 
140.4, 113.5, 110.5, 51.2, 36.2, 28.3, 22.3. HR-MS: m/z calculated for C10H14O3 [M+Na]+: 205.0841; 
found: 205.0844. 
 
General procedure for hydrolysis 
The furan ester (1 eq.) was dissolved in a sufficient amount of 1:1 THF:H2O solution. Lithium hydroxide 
(2.5 eq.) was added and the reaction mixture was stirred for a minimum of overnight at either room 
temperature or 65 ℃. The THF was removed in vacuo and the remaining aqueous phase was acidified 
with concentrated HCl until a white precipitate formed. The precipitate was extracted with diethyl ether 
and the organic layer was dried over Na2SO4, filtered and concentrated in vacuo to afford a white or 
yellowish solid as the desired product. 
 
4-(Hydroxymethyl)-2-isobutylfuran-3-carboxylic acid (MMF1)  
 
Yield: 85%. 1H NMR (400 MHz, CDCl3) δ: 0.94 (d, J = 6.5 Hz, 6H), 2.09 (m, 1H), 2.88 (d, J = 7.0 Hz, 
2H), 4.62 (s, 2H), 7.29 (s, 1H), 8.78 (br s, 2H). 13C NMR (100 MHz, CDCl3) δ: 170.0, 166.1, 138.8, 125.3, 
112.2, 55.6, 36.8, 28.3, 22.4. HR-MS: m/z calculated for C10H14O4 [M+Na]+: 221.0784; found: 221.0781. 
 
4-(Hydroxymethyl)-2-propylfuran-3-carboxylic acid (MMF2)  
 
Yield: 88%. 1H NMR (400 MHz, CDCl3) δ: 0.94 (t, J = 7.5 Hz, 3H), 1.71 (sext, J = 7.5 Hz, 2H), 2.97 (t, J 
= 7.5 Hz, 2H), 4.63 (s, 2H), 7.28 (s, 1H), 8.12 (br s, 2H). 13C NMR (100 MHz, CDCl3) δ: 169.8, 166.6, 









4-(Hydroxymethyl)-2-isopentylfuran-3-carboxylic acid (MMF3) 
 
Yield: 97%. 1H NMR (400 MHz, CDCl3) δ: 0.93 (d, J = 6.5 Hz, 6H), 1.57 (m, 3H), 3.00 (t, J = 7.5 Hz, 
2H), 4.62 (s, 2H), 7.27 (s, 1H), 8.07 (br s, 2H). 13C NMR (100 MHz, CDCl3) δ: 169.7, 166.9, 138.7, 125.4, 
111.5, 55.6, 36.7, 27.7, 26.0, 22.3. HR-MS: m/z calculated for C11H16O4 [M+Na]+: 235.0941; found: 
235.0942. 
 
2-Butyl-4-(hydroxymethyl)furan-3-carboxylic acid (MMF4) 
 
Yield: 77%. 1H NMR (400 MHz, CDCl3) δ: 0.93 (t, J = 7.5 Hz, 3H), 1.36 (sext, J = 7.5 Hz, 2H), 1.68 (quin, 
J = 7.5 Hz, 2H), 3.00 (t, J = 7.5 Hz, 2H), 4.62 (s, 2H), 7.28 (s, 1H), 8.07 (br s, 2H). 13C NMR (100 MHz, 
CDCl3) δ: 169.8, 166.8, 138.7, 125.3, 111.6, 55.6, 30.0, 27.9, 22.3, 13.7. HR-MS: m/z calculated for 
C10H14O4 [M+Na]+: 221.0784; found: 221.0781. 
 
4-(Hydroxymethyl)-2-pentylfuran-3-carboxylic acid (MMF5) 
 
Yield: 93%. 1H NMR (400 MHz, CDCl3) δ: 0.89 (t, J = 7.0 Hz, 3H), 1.33 (m, 4H), 1.68 (quin, J = 7.5 Hz, 
2H), 2.99 (t, J = 7.5 Hz, 2H), 4.63 (s, 2H), 7.28 (s, 1H), 8.16 (br s, 2H). 13C NMR (100 MHz, CDCl3) δ: 
169.7, 166.7, 138.7, 125.3, 111.6, 55.6, 31.4, 28.1, 27.5, 22.3, 13.9. HR-MS: m/z calculated for 
C11H16O4 [M+Na]+: 235.0941; found: 235.0941. 
 
4-(Hydroxymethyl)-2-methylfuran-3-carboxylic acid (MMF analogue 2) 
 
Yield: 72%. 1H NMR (500 MHz, CDCl3) δ: 2.61 (s, 3H), 4.60 (s, 2H), 6.28 (br s, 2H), 7.27 (s, 1H). 13C 
NMR (125 MHz, CDCl3) δ: 170.0, 163.3, 138.8, 125.7, 112.0, 55.8, 14.7. HR-MS: m/z calculated for 






2-Ethyl-4-(hydroxymethyl)furan-3-carboxylic acid (MMF analogue 3) 
 
Yield: 93%. 1H NMR (500 MHz, CDCl3) δ: 1.27 (t, J = 7.5 Hz, 3H), 3.03 (q, J = 7.5 Hz, 2H), 4.60 (s, 2H), 
5.70 (br s, 2H), 7.28 (s, 1H). 13C NMR (125 MHz, CDCl3) δ: 170.0, 168.1, 138.9, 125.7, 111.0, 55.8, 
22.0, 12.2. HR-MS: m/z calculated for C8H10O4 [M+Na]+: 193.0471; found: 193.0466. See 
Supplementary Figures 8-10.    
 
4-(Hydroxymethyl)-2-isopropylfuran-3-carboxylic acid (MMF analogue 4) 
 
Yield: 95%. 1H NMR (500 MHz, CDCl3) δ: 1.28 (d, J = 7.0 Hz, 6H), 3.80 (sept, J = 7.0 Hz, 1H), 4.60 (s, 
2H), 7.29 (s, 1H). 13C NMR (125 MHz, CDCl3) δ: 171.1, 170.3, 138.8, 125.5, 110.1, 55.8, 27.8, 20.8. 
HR-MS: m/z calculated for C9H12O4 [M+Na]+: 207.0628; found: 207.0629. See Supplementary Figures 
11-13. 
 
2-Hexyl-4-(hydroxymethyl)furan-3-carboxylic acid (MMF analogue 5) 
 
Yield: 76%. 1H NMR (500 MHz, CDCl3) δ: 0.89 (t, J = 6.5 Hz, 3H), 1.31(m, 6H), 1.68 (quin, J = 7.5 Hz, 
2H), 3.00 (t, J = 7.5 Hz, 2H), 4.60 (s, 2H), 7.28 (s, 1H). 13C NMR (125 MHz, CDCl3) δ: 170.3, 167.4, 
138.9, 125.6, 111.5, 55.8, 31.6, 29.0, 28.4, 28.0, 22.7, 14.2. HR-MS: m/z calculated for C12H18O4 
[M+Na]+: 249.1097; found: 249.1105. See Supplementary Figures 14-16. 
 
2-Heptyl-4-(hydroxymethyl)furan-3-carboxylic acid (MMF analogue 6) 
 
Yield: 86%. 1H NMR (500 MHz, CDCl3) δ: 0.88 (t, J = 7.0 Hz, 3H), 1.30 (m, 8H), 1.68 (quin, J = 7.5 Hz, 
2H), 2.99 (t, J = 7.5 Hz, 2H), 4.60 (s, 2H), 7.28 (s, 1H). 13C NMR (125 MHz, CDCl3) δ: 170.3, 167.3, 
138.9, 125.6, 111.6, 55.8, 31.8, 29.3, 29.1, 28.4, 28.0, 22.8, 14.2. HR-MS: m/z calculated for C13H20O4 




2-(But-3-enyl)-4-(hydroxymethyl)furan-3-carboxylic acid (MMF analogue 7) 
 
Yield: 97%. 1H NMR (500 MHz, CDCl3) δ: 2.45 (q, J = 7.5 Hz, 2H), 3.11 (t, J = 7.5 Hz, 2H), 4.61 (s, 2H), 
5.00 (dd, J = 10.0 and 1.5 Hz, 1H), 5.06 (dd, J = 17.0 and 1.5 Hz, 1H), 5.84 (ddt, J = 17.0, 10.0 and 6.5 
Hz, 1H), 7.29 (s, 1H). 13C NMR (125 MHz, CDCl3) δ: 170.1, 166.1, 139.1, 136.9, 125.6, 115.6, 111.9, 
55.8, 31.9, 27.9. HR-MS: m/z calculated for C10H12O4 [M+Na]+: 219.0628; found: 219.0624. See 
Supplementary Figures 20-22. 
 
2-sec-Butyl-4-(hydroxymethyl)furan-3-carboxylic acid (MMF analogue 8) 
 
Yield: 87%. 1H NMR (500 MHz, CDCl3) δ: 0.85 (t, J = 7.5 Hz, 3H), 1.25 (d, J = 7.0 Hz, 3H), 1.67 (m, 
2H), 3.61 (sext, J = 7.0 Hz, 1H), 4.61 (s, 2H), 7.30 (s, 1H). 13C NMR (125 MHz, CDCl3) δ: 170.4, 170.3, 
139.0, 125.3, 111.3, 55.8, 34.5, 28.5, 18.7, 12.1. HR-MS: m/z calculated for C10H14O4 [M+Na]+: 
221.0784; found: 221.0780. See Supplementary Figures 23-25. 
 
4-(Hydroxymethyl)-2-(2-methoxyethyl)furan-3-carboxylic acid (MMF analogue 9) 
 
Yield: 95%. 1H NMR (500 MHz, CDCl3) δ: 3.28 (t, J = 6.5 Hz, 2H), 3.38 (s, 3H), 3.72 (t, J = 6.5 Hz, 2H), 
4.59 (s, 2H), 7.31 (s, 1H). 13C NMR (125 MHz, CDCl3) δ: 168.6, 162.4, 139.5, 125.9, 113.5, 70.3, 58.9, 
55.7, 29.0. HR-MS: m/z calculated for C9H12O5 [M+Na]+: 223.0577; found: 223.0577. See 
Supplementary Figures 26-28. 
 
2-iso-Butyl-4-methylfuran-3-carboxylic acid (MMF analogue 11) 
 
Refluxed for 3 days. Yield: 78%. 1H NMR (400 MHz, CDCl3) δ: 0.94 (d, J = 6.5 Hz, 6H), 2.10 (non, J = 
6.5 Hz, 1H), 2.18 (d, J = 1.0 Hz, 3H), 2.89 (d, J = 7.5 Hz, 2H), 7.08 (d, J = 1.0 Hz, 1H), 12.37 (br s, 1H). 
13C NMR (100 MHz, CDCl3) δ: 171.0, 165.3, 138.2, 121.5, 113.2, 37.0, 28.4, 22.6, 10.2. HR-MS: m/z 





2-iso-Butylfuran-3-carboxylic acid (MMF analogue 12)   
 
Refluxed for 3 days. Yield: 85%. 1H NMR (500 MHz, CDCl3) δ: 0.95 (d, J = 6.5 Hz, 6H), 2.11 (non, J = 
6.5 Hz, 1H), 2.91 (d, J = 7.0 Hz, 2H), 6.70 (d, J = 2.0 Hz, 1H), 7.28 (d, J = 2.0 Hz, 1H). 13C NMR (125 
MHz, CDCl3) δ: 170.1, 164.3, 140.9, 113.3, 111.0, 36.5, 28.5, 22.5. HR-MS: m/z calculated for C9H12O3 
[M+H]+: 169.0859; found: 169.0860. See Supplementary Figures 32-34. 
 
Synthesis of MMF analogue 1 
4-(Ethoxycarbonyl)furan-3-carboxylic acid 
 
To a solution of diethyl furan-3,4-dicarboxylate (0.1 g, 0.47 mmol) in 2ml ethanol stirred at room 
temperature was added NaOH (0.018 g, 0.47 mmol) as a fine powder. The reaction was monitored by 
TLC indicating completion after 3 days. The solvent was removed in vacuo and the white solid dissolved 
in DCM was washed with 5 ml 1M NaHCO3 solution. The aqueous layer was acidified with 1M HCl 
solution and extracted with DCM. The combined organic layers was washed with brine, dried over 
MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography (hexane/diethyl 
ether = 2:1 v/v) to afford 4-(ethoxycarbonyl)furan-3-carboxylic acid (0.044 g, 0.24 mmol, 51%) as white 
solid. 1H NMR (400 MHz, MeOD) δ: 1.27 (t, J = 7.0 Hz, 3H), 4.28 (q, J = 7.0 Hz, 2H), 8.14 (d, J = 2.0 
Hz, 1H), 8.16 (d, J = 2.0 Hz, 1H). 13C NMR (100 MHz, MeOD) δ: 166.0, 164.4, 152.3, 151.6, 119.9, 
118.3, 63.2, 14.4. HR-MS: m/z calculated for C8H8O5 [M+H]+: 185.0444; found: 185.0445. 
 
4-(Hydroxymethyl)furan-3-carboxylic acid (MMF analogue 1) 
 
A solution of 4-(ethoxycarbonyl)furan-3-carboxylic acid (0.150 g, 0.82 mmol) in 0.7 ml dry THF was 
added by syringe to a stirring solution of lithium borohydride (1 M, 0.47 mmol)  in THF at 0 °C under 
argon. The reaction mixture was allowed to warm up to room temperature while being stirred for 3 h. 
The reaction mixture was then cooled to 0 °C and ice cold THF-water (3 ml, 1:1) was added slowly with 
vigorous stirring followed by acidification with concentrated HCl. The resulting clear solution was 
extracted with DCM. The combined organic layers was washed with brine, dried over MgSO4 and 
concentrated in vacuo to afford MMF analogue 1 (0.075 g, 0.53 mmol, 64%) as white powder. The NMR 
spectra of analogue 1 are identical to the reported data51. 1H NMR (400MHz, MeOD) δ: 4.57 (s, 2H), 
7.41 (s, 1H), 7.98 (s, 1H). 13C NMR (100MHz, MeOD) δ: 166.9, 150.9, 142.9, 127.2, 119.2, 56.5. HR-




Synthesis of SCB1 
SCB1 was prepared according to modification of a reported procedure for A-factor52. The synthetic route 
for SCB1 is described in Extended Data Figure 5a. The step involving acyl Meldrum’s acid was 
simplified by using EDC/DMAP in one step instead of acid chloride formation and subsequent acylation 
in two steps. Treatment with sodium cyanoborohydride in acetic acid provided the desired double 
reduction product of the alkene and ketone in one step, which was followed by deprotection and column 




Dimethyl malonate (2.6 ml, 22.1 mmol) was slowly added to a stirring suspension of NaH (0.76 g, 30.0 
mmol) in 60 ml THF at 0 ℃ and the mixture was stirred at the same temperature for 30 min. 1-Bromo-
4-methylpentane (3.0 ml, 20.0 mmol) and TBAI (1.51 g, 4.0 mmol) were added and stirred at 0 ℃ for 
30 min before the solution was allowed to warm to room temperature and heated to reflux overnight. 
The reaction mixture was concentrated in vacuo, acidified with 3 M HCl solution and extracted with 
DCM. The DCM solution was washed with water and brine, dried over anhydrous MgSO4 and 
concentrated in vacuo. The residue was purified by column chromatography (petroleum ether/ethyl 
acetate = 10:1 v/v) to give dimethyl 2-(4-methylpentyl)malonate (3.54 g, 16.4 mmol, 82%) as colourless 
oil. 1H NMR (300 MHz, CDCl3) δ: 0.80 (d, J = 6.5 Hz, 6H), 1.09-1.17 (m, 2H), 1.20-1.30 (m, 2H), 1.48 
(non, J = 6.5 Hz, 1H), 1.82 (q, J = 8.0 Hz, 2H), 3.31 (t, J = 7.5 Hz, 1H), 3.68 (s, 6H). 13C NMR (75 MHz, 
CDCl3) δ: 169.8, 52.3, 51.6, 38.3, 28.9, 27.5, 25.0, 22.3. HR-MS: m/z calculated for C11H20O4 [M+H]+: 




2-(4-Methylpentyl)malonate (3.54 g, 16.4 mmol) was dissolved in a mixture of KOH (9.6 g, 171.4 mmol) 
in 30 ml water and 60 ml methanol and the mixture was stirred overnight at room temperature. The 
methanol was removed in vacuo and the remaining aqueous solution was washed with DCM, acidified 
with 3M HCl solution and extracted with DCM. The DCM layers were combined, dried over anhydrous 
MgSO4 and evaporated to yield 2-(4-methylpentyl)malonic acid (2.93 g, 15.6 mmol, 95%) as white 
crystals. 1H NMR (300 MHz, CDCl3) δ: 0.87 (d, J = 6.5 Hz, 6H), 1.17-1.27 (m, 2H), 1.33-1.44 (m, 2H), 
1.55 (non, J = 6.5 Hz, 1H), 1.92 (q, J = 8.0 Hz, 2H), 3.44 (t, J = 7.5 Hz, 1H), 10.73 (br s, 2H). LR-MS: 
[M-H]
－







2-(4-Methylpentyl)malonic acid (2.93 g, 15.6 mmol) was dissolved in 30 ml DMF and the mixture was 
refluxed overnight. 50 ml 5% NaHCO3 solution was added and the mixture was washed with hexane to 
remove the neutral impurities. The aqueous solution was acidified with 3 M HCl solution and extracted 
with DCM. The DCM solution was washed with brine, dried over anhydrous MgSO4 and concentrated 
in vacuo to give crude product (2.2 g, quantitative) as yellow oil. 1H NMR (300 MHz, CDCl3) δ: 0.85 (d, 
J = 7.0 Hz, 6H), 1.14 - 1.21 (m, 2H), 1.27 - 1.38 (m, 2H), 1.52 (non, J = 6.5 Hz, 1H), 1.60 (quin, J = 
7.5 Hz, 2H), 2.34 (t, J = 7.5 Hz, 2H), 11.73 (br s, 1H). 13C NMR (75 MHz, CDCl3) δ: 180.7, 38.5, 34.1, 




EDC·HCl (2.93 g, 15.3 mmol) was added to a solution of 6-methylheptanoic acid (2.20 g, 15.3 mmol) 
in 20 ml DCM and the mixture was cooled to 0 ℃. After stirring for 5 min, 4-dimethylaminopyridine (3.73 
g, 30.6 mmol) dissolved in 10 ml DCM was added, followed by Meldrum’s acid (2.20 g, 15.3 mmol) 
dissolved in 10 ml DCM. The reaction mixture was stirred under argon at room temperature for 18 h. 
The mixture was diluted with 20 ml DCM and washed twice with 1 M HCl, once with brine and once with 
water. After drying the organic phase over MgSO4, the solvent was removed in vacuo and the residue 
was purified by column chromatography to yield acyl Meldrum’s acid (2.0 g, 7.4 mmol, 48.4%) as yellow 
oil. 1H NMR (300 MHz, CDCl3) δ: 0.79 (d, J = 6.5 Hz, 6H), 1.12-1.17 (m, 2H), 1.28-1.38 (m, 2H), 1.47 
(non, J = 6.5 Hz, 1H), 1.61 (quin, J = 7.5 Hz, 2H), 1.66 (s, 6H), 2.99 (t, J = 7.5 Hz, 2H), 15.23 (s, 1H). 
13C NMR (75 MHz, CDCl3) δ: 170.3, 159.8, 104.4, 91.0, 38.2, 35.4, 27.5, 26.9, 26.4, 26.1, 22.2. LR-MS: 
[M-H]
－




tert-Butyldimethylsilyl chloride (2.67 g, 17.8 mmol) dissolved in 10 ml DMF was added to a mixture of 
dihydroxyacetone (5 g, 55.6 mmol) and imidazole (1.51 g, 22.2 mmol) in 50 ml DMF at 0 °C. The 
reaction was stirred at room temperature for 17 h. 50 ml water was added and the mixture was extracted 
with diethyl ether. The organic phase was washed with brine, dried over anhydrous MgSO4 and 
concentrated in vacuo. The residue was purified by column chromatography (petroleum ether/ethyl 
acetate = 5:1 v/v) to give product (1.82 g, 8.8 mmol, 50%) as colourless oil. 1H NMR (300 MHz, CDCl3) 
δ: 0.12 (s, 6H), 0.90 (s, 9H), 2.99 (br s, 1H), 4.31 (s, 2H), 4.50 (s, 2H), further signals at 3.43-4.24 due 
to formation of the intermolecular ketal compounds. 13C NMR (75 MHz, CDCl3) δ: 210.9, 25.7, 18.2, 5.6, 
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1-((tert-Butyldimethylsilyl)oxy)-3-hydroxy propan-2-one (1 eq.) and acyl Meldrumʼs acid (1.2 eq.) were 
added to 2 ml toluene already heated to 110 °C. The reaction mixture was refluxed for 3 h at which 
point was added 0.5 more equivalents of acyl Meldrumʼs acid. After stirring for another 5 h, the mixture 
was allowed to stand at -20 °C for 19 h and purified by column chromatography (hexanes/acetone = 
60:1 v/v) without removal of toluene to obtain butenolide as bright yellow oil in 33% yield. 1H NMR (300 
MHz, CDCl3) δ: 0.09 (s, 6H), 0.84 (d, J = 6.5 Hz, 6H), 0.89 (s, 9H), 1.10-1.36 (m, 4H), 1.47-1.63 (m, 
3H), 2.96 (t, J = 7.5 Hz, 2H), 4.98 (s, 2H), 5.06 (s, 2H). 13C NMR (75 MHz, CDCl3) δ: 197.1, 181.2, 
170.6, 122.4, 70.2, 61.8, 41.6, 38.7, 29.7, 27.8, 26.9, 25.7, 23.4, 22.6, -5.7. HR-MS: m/z calculated for 
C19H34O4Si [M+H]+: 355.2299; found: 355.2306. 
 
4-(((tert-Butyldimethylsilyl)oxy)methyl)-3-(1-hydroxy-6-methyl heptyl) dihydrofuran-2(3H)-one 
 
Butenolide (1 eq.) in AcOH was added dropwise to a solution of NaBH3CN (2 eq.) in AcOH at 10°C and 
the mixture was stirred at room temperature for 8 h. After removal of AcOH in vacuo, the oily residue 
was diluted with ethyl acetate and washed three times with 5% NaHCO3 solution and once with brine. 
After drying the organic phase over MgSO4, the solvent was removed in vacuo and the residue was 
purified by column chromatography (hexanes/ethyl acetate = 7:1 v/v) to yield reduction product as 
colourless oil in 49% yield. The reduction would result in the formation of three stereogenic centres in 
the molecule so NMR spectra contain a mixture of different stereoisomers. This resulted in excessive 
peaks and inaccurate integration. The diastereoisomers were isolated in the next step after deprotection 






TBDMS-protected butyrolactone was dissolved in a mixture of THF:HCOOH:H2O (6:3:1) and stirred 
overnight at room temperature. Reactions were brought up to pH 4 with saturated aqueous NaHCO3 
and extracted with ethyl acetate. Ethyl acetate extracts were combined, dried over MgSO4 and 
concentrated in vacuo. The product was purified by flash column chromatography (hexanes/ethyl 
acetate = 1:1 v/v) to give racemic SCB1 as colourless oil in 43% yield, as well as a pair of their 
diastereoisomers. The NMR spectra of SCB1 enantiomers are identical to the reported data for SCB153. 
1H NMR (400 MHz, CDCl3) δ: 0.86 (d, J = 6.5 Hz, 6H), 1.14-1.20 (m, 2H), 1.26-1.39 (m, 4H), 1.47-1.55 
(m, 2H), 1.57-1.64 (m, 1H), 2.65 (dd, J = 9.5 and 4.5 Hz, 1H), 2.74-2.81 (m, 1H), 3.68 (dd, J = 10.5 and 
6.5 Hz, 1H), 3.75 (dd, J = 10.5 and 5.0 Hz, 1H), 3.98 (t, J = 9.0 Hz, 1H), 4.01 (ddd, J = 9.0, 4.5 and 3.0 
Hz, 1H), 4.42 (t, J = 8.5 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ: 70.8, 68.3, 63.0, 49.1, 40.1, 38.8, 33.9, 
27.9, 27.2, 26.1, 22.6. HR-MS: m/z calculated for C13H24O4 [M+Na]+: 267.1567; found: 267.1565.  
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Supplementary Table 1 Strains and plasmids used in this study. 
Strains / 
Plasmids 
Relevant properties Source or Reference 
Strains   
   Streptomyces 
coelicolor 
  
M145 SCP1-, SCP2- (Methylenomycin-sensitive) [54] 
W81 
M145 with pCC002::attB (MMF minus, 
methylenomycin minus) 
[3] 
   E. coli   
TOP10 One shot chemically competent cells Invitrogen 
BL21 Star (DE3) 
F-ompT hsdSB (rB-, mB-) galdcmrne131 (DE3) 
T7 promoter based expression system 
Invitrogen 
B834 (DE3) Met auxotrophic strain for production of Se-Met-MmfR  Novagen 
Plasmids   
pET151/D-TOPO 
T7 expression vector, 
ampicillin resistance 
Invitrogen 
pET151-mmfR - This study 
pET151-mmfR Q130E - This study 
pET151-mmfR Y85F - This study 
pET151-mmfR Y144F - This study 
C73_787 
Integrative cosmid containing the full methylenomycin 
cluster including the MMFs biosynthetic genes 
[55] 
 














Supplementary Table 2 Primers used for cloning of mmfR, mutagenesis and PCR amplification of the 
intergenic regions for EMSAs. Fw: forward primer, Rev: reverse primer. 





Cloning of mmfR gene (SCP1.242c – 
642 bp) into pET151/D-TOPO vector 















Q5; New England Biolabs 





Entire intergenic region between 





Entire intergenic region between 
mmyB and mmyY 
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Supplementary Table 3 Crystallographic data collection and refinement statistics. 
 MmfR-MMF2 complex MmfR (SeMet) MmfR (Native) 
Data collection    
PDB ID 6SRN  7KY1 
Space group P41212 P41212 C222 
Cell dimensions      
    a, b, c (Å) 67.21, 67.21, 92.82 67.04, 67.04, 93.91 60.50, 115.72, 53.09 
        () 90, 90, 90 90, 90, 90 90, 90, 90 
    
Wavelength 0.9795 0.9793 0.9686 
Resolution (Å) 42.3-1.5 (1.58-1.5) * 93.9-2.2 (2.32-2.2) 53.6-1.50 (1.56-1.50)  
Rsym or Rmerge 0.082 (1.189) 0.137 (0.768) 0.053 (0.659) 
I / I 17.9 (2.2) 18.5 (4.5) 16.0 (2.2) 
Completeness (%) 99.9 (99.6) 100 (100) 99.0 (99.5) 
Redundancy 11.7 (11.7) 12.7 (12.8) 4.3 (4.1) 
CC1/2 
 
99.9 (76.2) 99.7 (81.4) 100.0 (84.7) 
Refinement    
Resolution (Å) 42.3-1.5  53.6-1.50 
No. reflections 34705  29976 
Rwork / Rfree 0.174 / 0.207  0.189 / 0.213 
No. atoms    
    Protein 1480  1507 
    Ligand 13   
    Water/Glycerol 256/6  229 
B-factors    
    Protein 13.4  24.1 
    Ligand/ion 13.2   
    Water 33.4  37.0 
R.m.s deviations    
    Bond lengths (Å) 0.014  0.007 
    Bond angles () 1.9  0.9 
Ramachandran statistics    
    Favoured (No., %) 183, 99  189, 98 
    Allowed (No., %) 2, 1  3, 2 





Supplementary Table 4 Cryo-EM data collection and processing for the MmfR-MARE1 complex.     
 
(Data set 1) (Data set 2) 
Data collection and processing   
Magnification    165,000 165,000 
Voltage (kV) 300 300 
Electron exposure (e–/Å2) 50 50 
Defocus range (μm) 0.5 0.5 
Pixel size (Å) 0.84 0.84 
Initial particle images (no.) 181,409 292,512 
   
Final  particle images (no.)                                   311088 
                                  C1 
                                  4.5 
                                  0.143 
                                 -94.02 
                                  4PXI 
 
                                  6777 
                                  756 
                                  38 
 
                                  97.86 
                                  2.14 
                                  0.0 
 
                                  EMD-20781 
Symmetry imposed 
Map resolution (Å) 
    FSC threshold 
Map sharpening B factor (Å2) 
Initial model used (PDB code) 
Model composition 
    Non-hydrogen atoms 
    Protein residues 
    DNA residues 
Ramachandran plot 
    Favored (%) 
    Allowed (%) 







Supplementary equation 1 
𝐴𝑛𝑖𝑠𝑜𝑡𝑟𝑜𝑝𝑦 (𝑟) =  
𝐼𝑉𝑉 − 𝐺(𝜆𝑒𝑚)𝐼𝑉𝐻
𝐼𝑉𝑉 + 2𝐺(𝜆𝑒𝑚)𝐼𝑉𝐻
    
IVV is intensity with excitation and emission polarizers mounted vertically, whereas IVH is intensity with 
vertical excitation and horizontal emission polarizers. G is the so-called G-factor, which accounts for 
optical and systematic errors. em is the emission wavelength. 
 
Supplementary equation 2 
𝑦 = 𝑟0 + (𝑟𝑚𝑎𝑥 − 𝑟0)
𝑥ƞ
𝑘ƞ+𝑥ƞ
      (𝑤ℎ𝑒𝑟𝑒 𝑟𝑚𝑎𝑥 − 𝑟0 > 0  𝑓𝑜𝑟 𝑏𝑖𝑛𝑑𝑖𝑛𝑔 𝑎𝑛𝑑 𝑓𝑜𝑟 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 𝑖𝑡 𝑖𝑠 < 0)         
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spectra for analogue 5. 
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Supplementary Fig. 17 | 1H-NMR spectrum of analogue 6.
Supplementary Fig. 18 | 13C-NMR spectrum of analogue 6.
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Supplementary Fig. 19 | Comparison of measured (top panel) and simulated (bottom panel) mass 
spectra for analogue 6. 
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Supplementary Fig. 20 | 1H-NMR spectrum of analogue 7.
Supplementary Fig. 21 | 13C-NMR spectrum of analogue 7.
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Supplementary Fig. 22 | Comparison of measured (top panel) and simulated (bottom panel) mass 
spectra for analogue 7. 
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Supplementary Fig. 23 | 1H-NMR spectrum of analogue 8.
Supplementary Fig. 24 | 13C-NMR spectrum of analogue 8.
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Supplementary Fig. 25 | Comparison of measured (top panel) and simulated (bottom panel) mass 
spectra for analogue 8. 
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Supplementary Fig. 26 | 1H-NMR spectrum of analogue 9.
Supplementary Fig. 27 | 13C-NMR spectrum of analogue 9.
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Supplementary Fig. 28 | Comparison of measured (top panel) and simulated (bottom panel) mass 
spectra for analogue 9. 
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Supplementary Fig. 29 | 1H-NMR spectrum of analogue 11.
Supplementary Fig. 30 | 13C-NMR spectrum of analogue 11.
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Supplementary Fig. 31 | Comparison of measured (top panel) and simulated (bottom panel) mass 
spectra for analogue 11. 
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Supplementary Fig. 32 | 1H-NMR spectrum of analogue 12.
Supplementary Fig. 33 | 13C-NMR spectrum of analogue 12.
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Supplementary Fig. 34 | Comparison of measured (top panel) and simulated (bottom panel) mass 
spectra for analogue 12. 
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Supplementary Fig. 35 | FA plots for release of MmfR from MARE1 by selected MMF analogues. 
Data points are the mean of three independent technical replicates (n=3) and error bars represent ± 1 
standard deviation. The EC50 (nM) calculated from each data set is shown. 
